iTeos: Developing IO Therapeutics For Hot And Cold Tumors

Emerging Company Profile: Not many young academic spin-outs can claim a clinical-stage collaboration with a big pharma, but iTeos Therapeutics ‒ a Belgian company developing novel cancer therapies ‒ can do just that.

Emerging Company Profile Regular column feature image Version 2

With the immuno-oncology space a battleground for large pharmaceutical companies, surely there isn't much a small biotech can offer? iTeos Therapeutics, a 2011 spin off from Ludwig Cancer Research, believes otherwise, CEO and founder Michel Detheux told Scrip.

"We're targeting hot and cold tumors," he explained. "This concept in targeting the tumor microenvironment is becoming more and more...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip